Researchers have discovered that certain patients with obstructive sleep apnea and obesity may experience much greater benefits from the GLP-1 medication tirzepatide than others.
The findings could help doctors better predict who is most likely to improve with treatment and who may still need additional therapies for sleep apnea.
The research was presented at the 2026 ATS International Conference and focused on people with obstructive sleep apnea, a condition that causes repeated breathing interruptions during sleep.
Obstructive sleep apnea, often shortened to OSA, affects millions of people worldwide. The condition happens when the muscles and tissues around the airway relax too much during sleep, causing airflow to become blocked. These repeated pauses in breathing can happen many times throughout the night.
People with sleep apnea often experience loud snoring, poor sleep quality, morning headaches, tiredness during the day, trouble concentrating, and mood problems. In severe cases, untreated sleep apnea may increase the risk of high blood pressure, heart disease, stroke, diabetes, and even early death.
Obesity is one of the strongest risk factors for sleep apnea because extra fat around the neck and throat can make the airway narrower and more likely to collapse during sleep.
In recent years, GLP-1 medications such as tirzepatide have become increasingly popular for treating obesity and type 2 diabetes. These medicines help regulate appetite and blood sugar levels, often leading to substantial weight loss.
Scientists have also found that weight loss from these medications may improve sleep apnea symptoms. However, doctors noticed that some patients improve dramatically while others show more modest changes.
To better understand this difference, researchers led by Dr. Scott Sands from Brigham and Women’s Hospital and Harvard Medical School analyzed data from an earlier clinical trial involving tirzepatide treatment in patients with obesity and sleep apnea.
The researchers discovered a subgroup of patients they described as “strong responders.” These patients experienced almost twice as much improvement in their sleep apnea severity compared to other patients.
The scientists then looked closely at what made these patients different.
Strong responders tended to be younger and had less severe obesity. They also showed several specific breathing and airway features linked to the underlying biology of sleep apnea.
One important feature was greater airway collapsibility, meaning their upper airways were more likely to close during sleep. Another factor involved instability in breathing control, known as high loop gain.
Loop gain describes how sensitive the body’s breathing system is to changes in oxygen and carbon dioxide levels. In people with high loop gain, breathing can become unstable and overreactive, which may worsen sleep apnea.
The strong responders also tended to wake up more easily when airflow became restricted.
At first, researchers were surprised that high loop gain predicted better response to tirzepatide treatment. But additional analysis suggested the medication may improve not only weight and airway collapse, but also breathing instability itself.
This means tirzepatide may affect multiple causes of sleep apnea at the same time.
According to Dr. Sands, the findings could eventually help doctors provide more personalized guidance for patients considering GLP-1 treatment.
Currently, doctors can usually only explain the average results from clinical studies. In general, previous studies have shown that tirzepatide can reduce sleep apnea severity by about half compared to placebo treatment.
However, the new research suggests that some patients may improve much more than average, while others may still need CPAP therapy or additional treatments.
CPAP, which stands for continuous positive airway pressure, remains one of the standard treatments for sleep apnea. These machines keep airways open during sleep by delivering pressurized air through a mask. While highly effective, some patients struggle to tolerate them comfortably.
The possibility that medications such as tirzepatide could help reduce sleep apnea severity has generated major interest among sleep specialists and obesity researchers.
The findings also reflect a larger shift happening in medicine toward personalized treatment. Instead of treating every patient the same way, doctors increasingly aim to understand the biological differences that influence treatment response.
The researchers hope future studies will examine sleep apnea outcomes across many different weight-loss approaches, including medications, lifestyle interventions, and surgical treatments.
Scientists believe this may eventually help match patients with the therapies most likely to work best for their specific type of sleep apnea.
If you care about weight loss, please read studies that hop extract could reduce belly fat in overweight people, and early time-restricted eating could help lose weight .
For more health information, please see recent studies about a simple path to weight loss, and results showing a non-invasive treatment for obesity and diabetes.
Source: Brigham and Women’s Hospital.
